Morepen Laboratories Limited has informed the Exchange about Investor Presentation
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Morepen Laboratories reported Q4 FY26 revenue of Rs. 472 crore, up 22% YoY, driven by 17% API growth and 31% Medical Devices growth. FY26 full-year revenue grew 8% to Rs. 1,703 crore. However, profitability declined significantly with PAT falling 35% to Rs. 66 crore and EBITDA dropping 20% to Rs. 135 crore, as manufacturing scale-up investments impacted near-term margins. The company secured a Rs. 823 crore multi-year manufacturing mandate with commercial production commenced and phased deliveries starting soon. Management targets EBITDA profile improvement from ~11% to 20%+ through capacity expansion (from ~500 KL to ~1,000 KL), better customer mix, and operating leverage from long-duration supply programs. The company maintains strong regulatory credibility with 4th consecutive USFDA inspection with NIL 483 observations.
The stock is transitioning from transactional API sales to higher-margin, long-duration manufacturing partnerships. Near-term profitability pressure is expected to reverse as the Rs. 823 crore mandate ramps up, supporting the targeted EBITDA margin expansion to 20%+.